Evidence map›Paper›PMID 39699794›Full record

ArticleMedical oncology (Northwood, London, England)2024

Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303).

Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, Jin Matsuyama, Yutaka Kimura, Toshio Shimokawa, Hisato Kawakami, Taroh Satoh, Takushi Yasuda, Hiroshi Furukawa

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Therapeutic strategy for scirrhous type gastric cancer.Japanese journal of clinical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masayuki ShinkaiDepartment of Surgery, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Motohiro ImanoDepartment of Surgery, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. imano@med.kindai.ac.jp.
Masaki YokokawaDepartment of Radiation Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Jin MatsuyamaDepartment of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Osaka, Japan.
Yutaka KimuraDepartment of Gastroenterological Surgery, Sakai City Medical Center, Sakai, Osaka, Japan.
Toshio ShimokawaClinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
Hisato KawakamiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Taroh SatohCenter for Cancer Genomics and Precision Medicine, Osaka University Hospital, Suita, Osaka, Japan.
Takushi YasudaDepartment of Surgery, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Hiroshi FurukawaDepartment of Surgery, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose The prognosis for type 4 and large type 3 gastric cancer (GC) is extremely poor, especially in elderly patients (≥ 75 years). To improve the prognosis of these types of GC, we performed a phase I study to determine the recommended dose (RD) of S-1 combined with neoadjuvant radiotherapy. Methods Patients with clinically resectable type 4 and large type 3 GC were enrolled to successive cohorts in a conventional 3 + 3 design. Three dose levels were designed, as follows: level 0: S-1 60 mg/m

Indexed as

Drug CombinationsNeoadjuvant TherapyOxonic AcidStomach NeoplasmsTegafurAgedAged, 80 and overAntimetabolites, AntineoplasticChemoradiotherapyFemaleHumansMaleAntimetabolites, AntineoplasticDrug CombinationsOxonic AcidS 1 (combination)TegafurChemoradiotherapyElderlyGastric cancerLarge Type 3S-1Type 4

Identifiers

PMID39699794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.